Researchers find potential in nerve block treatment for post-COVID smell distortions
By Prabhjot Sohal
Imagine taking the first sip of your morning coffee, only to be hit by an overwhelming, gut-churning stench.
This altered sense of smell is a reality for many living with a post-COVID smell dysfunction called parosmia – a disorder that twists even comforting smells into repulsive ones. While post-COVID parosmia wreaks havoc on both physical and mental well-being, data on its symptoms, progression, effect on the quality of life and effectiveness of treatment options is sparse.
Dr. Leigh Sowerby, associate professor in the Department of Otolaryngology-Head and Neck Surgery
A recent study by Schulich Medicine & Dentistry researchers Dr. Leigh J Sowerby, Dr. Zaid Almubarak, Dr. Ameen Biadsee and Taciano Rocha offers crucial insights into some key characteristics and treatment options for post-COVID parosmia.
The study, published in The Journal of Laryngology & Otology, identifies Stellate Ganglion Block (SGB) – a procedure involving injecting a local anesthetic into the stellate ganglion, a collection of nerves in the neck – as a possible effective treatment to help alleviate the distorted sense of smell in patients.
“The stellate ganglion controls sympathetic signals to the head, neck, arms and part of the chest. Temporarily blocking these signals through an anesthetic injection could alleviate the distorted sense of smell in patients as it appears that part of the problem is in how the brain is perceiving the signal,” said Sowerby, associate professor in the Department of Otolaryngology-Head and Neck Surgery at Schulich Medicine.
“It’s a procedure with minimal risk and of all the strategies patients have tried, from smell training to nasal corticosteroid sprays, SGB appears to be the most effective in treating post-COVID parosmia.”
For this study, 209 adult patients registered with two social media groups – AbScent and Facebook COVID anosmia/parosmia were surveyed. Most respondents were based out of the U.S.
According to Sowerby, the senior author of the study, this problem is under-recognized and under-treated, which is why the researchers had to rely on an online survey.
Top 10 triggers for parosmia
Onion, Garlic, Meat, Coffee, Chicken, Eggs, Peanut butter, Chocolate, Fried food, Perfume
According to the survey results, smell training was the most commonly adopted treatment option, used by 74 per cent of the patients, followed by the use of nasal corticosteroid sprays and vitamin A drops, taken by 49 per cent and 20 per cent of patients, respectively. While only 16 per cent of patients underwent SGB therapy, it showed the highest effectiveness, with a substantial 45 percent of these patients reporting significant improvement.
Sowerby and his team are now looking to conduct a clinical trial to get further insights.
“This survey is the first step to get more data on patients and their experiences. Further research is needed to understand the efficacy and the benefit of SGB for post-COVID parosmia,” he said.
SGB is primarily used to diagnose and treat chronic neuropathic pain conditions linked to the sympathetic nervous system, such as complex regional pain syndrome and phantom limb pain. In addition to pain management, SGB has been employed to address circulation problems and various nerve injuries. Moreover, it's currently being investigated in treating mental health conditions like post-traumatic stress disorder (PTSD), depression, and anxiety.
Parosmia’s impact on the body and mind
(From most reported to least reported)
Depression
Loss of appetite
Weight loss
Anxiety
Weight gain
Nausea
Frustration
Low energy
Mood swings
Suicidal thoughts
Clinical features of parosmia and impact on quality of life
The findings of the study showed that patients predominantly reported a loss of smell about three days after their initial COVID-19 symptoms, a recovery around four weeks later and the onset of parosmia symptoms approximately 12 weeks post-infection. A total of 42 per cent reported no improvement in their condition and 22 per cent experienced slight improvement. Only three per cent of respondents reported a full recovery. The study found 80 per cent of the respondents with parosmia were not vaccinated against COVID-19 at the time of infection.
The findings also revealed that post-COVID parosmia had a serious impact on patients’ quality of life, with depression, appetite loss, significant weight loss and even suicidal thoughts reported among sufferers. Common food items like onion and garlic were reported as the top triggers for parosmia.
“The psychological impact of parosmia is substantial, with depression being the most reported condition,” said Sowerby.
“More than half of our respondents, 54 per cent, reported a significant impact on the quality of their life. There’s a clear need to identify effective treatment strategies and improve the lives of these patients.”
